ArticleJournal of racial and ethnic health disparities2026
The Impact of Race on Oncological Outcomes in Patients with an Initial Negative Prostate Biopsy: Results from a Contemporary U.S. Cohort.
Article in Journal of racial and ethnic health disparities, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExhaustive evidence about the impact of racial disparities in oncological outcomes after a negative prostate biopsy is still lacking. We explored the relationship between race and long-term oncological risk among men with an initial negative prostate biopsy using a contemporary U.S. COHORT:
methodsNon-Hispanic Black (NHB) and Non-Hispanic White (NHW) men who had a negative prostate biopsy at Henry Ford Health between 1995-2023 were included. An Area Deprivation Index (ADI)-score was assigned to each patient based on their residential census-block group. The higher the ADI, the more the area has a socio-economic disadvantage. Competing-risk methods were used to estimate the cumulative incidence of any PCa diagnosis, clinically significant PCa diagnosis, receipt of active treatment, Prostate Cancer Specific Mortality (PCSM) and Other Cause Mortality (OCM) for the entire cohort of patients, after stratification according to race. Fine-Gray regression models tested the impact of race on the aforementioned outcomes.
resultsWe included 17,446 men, 5,729 (30.3%) of whom were NHB. Within a median follow-up time of 7.8 years, the 15-years estimated rates of any PCa diagnosis, clinically significant PCa, active treatment and PCSM were 15.9% vs. 9.5%, 10.7% vs. 6.4%, 10.4% vs. 6.4% and 2.4% vs. 1.3%, for NHB versus NHW patients, respectively (all p-value < 0.0001). At multivariable analysis, NHB men had significantly higher hazard of any PCa (HR:1.90), clinically significant PCa (HR:1.91), active treatment for PCa (HR:1.84) and PCSM (HR:1.89) (all p < 0.001).
conclusionsNHB men, even after an initial negative prostate biopsy, face a higher risk of subsequent any PCa, clinically significant disease, active treatment and PCSM. Overall, these findings underscore the multifaceted impact of racial disparities on PCa prognosis.
Indexed as
Identifiers
41654700What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.